Dr. Shenlin Huang joined Biotheryx as Senior Director of Chemistry in June 2022. He became Executive Director of Chemistry in January 2024. Shenlin oversees the Company’s Medicinal Chemistry department, including database, computational chemistry and ADME/PK research. He previously served as Group Leader at AbbVie Oncology Discovery, where he led the company’s protein degradation program. Prior, Shenlin worked as Senior Research Investigator at Novartis Institutes for BioMedical Research where his team designed, synthesized and developed the FDA approved drug BRAFTOVI®. During this time, he also contributed to the development of several other clinical compounds. Prior, Shenlin was Senior Scientist at Johnson and Johnson Pharmaceutical. Dr. Huang received his Ph.D. in organic chemistry at the University of South Carolina and conducted his postdoctoral training at North Carolina State University.

• 

  Executive Director, Medicinal Chemistry in Biotheryx

  Degrading proteins. Saving lives.